Abstract: The present invention relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a pharmaceutical composition for the treatment and/or prevention of a virus infection.

Abstract: The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and/or for the provision of an increased barrier function of the gutmucosa.

Abstract: A probiotic fruit juice drink consisting of at least one species of probiotic bacteria chosen from Lactobacillus and at least one gas formation reducer chosen from acerola, pomegranate, cranberry, arqnia, blackcurrant, buckthorn or elderberry and any combination thereof and a primary fruit juice chosen from a citrus fruit juice or an pip fruit juice. The probiotic juice drink contains optionally a secondary fruit juice and optionally water.

Abstract: The invention refers to new strains of Bifidobacterium, especially of the species Bifidobacterium infantis, having the ability to survive in the intestinal tract and to produce glutamine and optionally arginine in vivo, as well as to compositions comprising said strains.

Abstract: The present invention relates to a method for modifying polyphenol containing plant material(s), wherein said method comprises: mixing at least one polyphenol containing material and at least one solvent to provide a mixture; heating the mixture to eliminate bacterial species present to provide a heated mixture; adding at least one polyphenol modifying strain of lactic acid bacteria and optionally at least one protein source, in optional order or simultaneously, to the heated mixture to provide a fermentation mixture; and subjecting the fermentation mixture to conditions suitable for fermentation of the fermentation mixture to provide a mixture of modified polyphenol containing plant material(s); and optionally eliminating the polyphenol modifying strain of lactic acid bacteria to provide a mixture of modified polyphenol containing plant material(s) free from living lactic acid bacteria.

Abstract: The present invention relates to a probiotic bacterial strain belonging to the genus Lactobacillus having the ability to colonize the human vagina, or a variant thereof. More specifically the probiotic bacterial strain belongs to a species chosen from the group comprising Lactobacillus plantarum, Lactobacillus crispatus, and Lactobacillus gasseri. Further it relates to its use as a medicament, a composition comprising the strain, the composition, e.g., being a food product or a pharmaceutical composition, a hygiene product, a biological pure culture of the strain, and a novel food.

Abstract: Use of one strain of Lactobacillus plantarum for the manufacture of a composition for increasing the diversity of the gastrointestinal tract by administration of said strain to an individual with a view to producing an increased diversity index compared to placebo is disclosed, as well as use of one strain of Lactobacillus plantarum for the manufacture of a composition for prophylactic treatment of a healthy individual against developing a low bacterial diversity (LBD); of an individual having LBD against developing one or more physiologically disturbed conditions, large intestine bacterial overgrowth (LIBO) or small intestine bacterial overgrowth (SIBO); and of an individual having LIBO or SIBO against developing one or more physiologically disturbed conditions, and a method for increasing said diversity.

Abstract: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.

Abstract: New strains of lactobacillus paracasei which can be used as probiotics in dairy products and which are characterized in surviving the gastrointestinal passage and giving a palatable cheese product when used as an adjunct in cheese manufacturing. The invention especially refers to the new strains Lactobacillus paracasei 8700:2, DSM 13434, and Lactobacillus paracasei 02A, DSM 13432. The invention also refers to dairy food products, such as cheese, containing said strains.

Abstract: The present invention relates to the use of at least one strain of Lactobacillus plantarum chosen from the group comprising Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum '299, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, and a part thereof, for the preparation of a composition for increasing the absorption of at least one kind of metal/metal ion in a mammal, preferably a human.

Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.

Abstract: The present invention relates to a probiotic bacterial strain belonging to the genus Lactobacillus having the ability to colonize the human vagina, or a variant thereof. More specifically the probiotic bacterial strain belongs to a species chosen from the group comprising Lactobacillus plantarum, Lactobacillus crispatus, and Lactobacillus gasseri. Further it relates to its use as a medicament, a composition comprising the strain, the composition, e.g., being a food product or a pharmaceutical composition, a hygiene product, a biological pure culture of the strain, and a novel food.

Abstract: The invention describes a sports drink, which in addition to conventional additives contains viable lactobacilli having a positive effect on human intestinal mucosa. The sports drink preferably also contains micronutrients and proteins. The invention also refers to a tablet for the preparation of such a sports drink, containing viable freeze-dried lactobacilli in combination with micronutrients. In addition to providing liquid and nutrients replacement, the sports drink also relieves the stress symptoms, which are associated with long physical exercise.

Abstract: The present invention provides a method of stabilizing immunoglobulins in a solution having a pH below 4 by adding cereals or hydrolysed cereal products in an amount sufficient to prevent degradation. The present invention also provides a health drink or sports drink comprising immunoglobulins in a solution having a pH of 2.7–3.8 containing cereals or hydrolysed cereal products in an amount sufficient to prevent degradation of the immunoglobulins.

Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.

Abstract: The invention refers to the use of a bacterial strain, preferably of the genus Lactobacillus or Propionibacterium, giving rise to increased amounts of propionic acid in the gut for the manufacture of a medicament for reduction of the level of oxidative stress factors, such as IL-6, reactive oxygen species (ROS), and adhesion molecules in mammals including man. The medicament can be used for the prophylaxis and/or treatment of chronic inflammatory diseases such as rheumatic diseases and psoriasis.

Abstract: The invention refers to the use of a bacterial strain, preferably of the genus Lactobacillus or Propionibacterium, giving rise to increased amounts of propionic acid in the gut for the manufacture of a medicament for reduction of the level of oxidative stress factors, such as IL-6, reactive oxygen species (ROS), and adhesion molecules in mammals including man. The medicament can be used for the prophylaxis and/or treatment of chronic inflammatory diseases such as rheumatic diseases and psoriasis.

Abstract: Novel strains Lactobacillus plantarum JI:1 and Lactobacillus species AC:3 are contained in an equine feed product. An oatmeal gruel fermented with said strains can be used for the prophylaxis or treatment of disturbances in the equine intestinal microflora, as well as gastritis.

Abstract: The invention refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level, and optionally cholesterol level, in blood. Said medicament can be utilized for the prophylaxis and/or treatment of circulatory diseases.

Abstract: The invention refers to the use of Lactobacillus plantarum 299v having a mannose-specific adhesin for the preparation of a pharmaceutical composition inhibiting the binding of pathogenic bacteria expressing mannose-specific adhesins to the epithelial cell surface. The strain of Lactobacillus plantiarum which can be used in the invention adheres to D-mannose-coated agarose beads. The invention also refers to the use of said strain for the preparation of a pharmaceutical composition to be used in prophylatic and/or curative treatment of bacterial translocation, gastroenteritis and other diseases caused by pathogenic bacteria expressing mannose-specific adhesins.